Enzyme – Page 5

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

1 year ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration

Black Diamond Therapeutics Refocuses on Lung Cancer Drug BDTX-1535 Amid Workforce Reduction

1 year ago talkbio0Tagged BDTX-1535, Black Populations, Diamond Therapeutics, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Mutation, Protein-tyrosine kinase inhibitor, Tagrisso

Black Diamond Therapeutics, workforce reduction, lung cancer drug, BDTX-1535, EGFR mutations, Tagrisso, tyrosine kinase inhibitor

Roche Invests $850 Million in Regor’s Next-Generation CDK Inhibitors for Breast Cancer Treatment

1 year ago talkbio0Tagged CDK, Cyclin-Dependent Kinases, genentech, inhibitors, Malignant neoplasm of breast, pharmaceutical acquisition, Regor, Roche (company)

Roche, Regor Pharmaceuticals, CDK inhibitors, breast cancer, Genentech, pharmaceutical acquisition

Roche Acquires Regor’s CDK Inhibitors for $850M to Enhance Breast Cancer Portfolio

1 year ago talkbio0Tagged CDK, Cyclin-Dependent Kinases, genentech, inhibitors, Malignant neoplasm of breast, pharmaceutical acquisition, Regor, Roche (company), transformative medicines

Roche, Regor Therapeutics, CDK inhibitors, breast cancer, Genentech, pharmaceutical acquisition, transformative medicines

FDA Approves Rybrevant for Third NSCLC Indication This Year

1 year ago talkbio0Tagged Approved, Epidermal Growth Factor Receptor, J&J, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, United States Food and Drug Administration

Rybrevant, NSCLC, FDA approval, J&J, EGFR mutations, lung cancer treatment

J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

1 year ago talkbio0Tagged Approved, chemotherapy-free regimen, Epidermal Growth Factor Receptor, Johnson & Johnson, lazertinib, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, United States Food and Drug Administration

Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen

Sun Pharma Secures FDA Approval for Leqselvi, a JAK Inhibitor for Severe Alopecia Areata

1 year ago talkbio0Tagged Alopecia, Approved, Dermatology field, Eli Lilly, Immunology, Inhibitor, Janus kinase, Leqselvi, Pfizer, Sun Pharma, United States Food and Drug Administration

Sun Pharma, Leqselvi, FDA Approval, Alopecia Areata, JAK Inhibitor, Pfizer, Lilly, Immunology, Dermatology

AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront

1 year ago talkbio0Tagged AstraZeneca, Cancer Therapeutic Procedure, Epidermal Growth Factor Receptor, licensing agreement, milestone payments, molecular glues, Neoplasms, Pinetree, Protein Degradation, Metabolic, protein degrader, royalties

AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment